子宮内膜症の世界市場レポート 2025年

子宮内膜症市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.3％で22億1,000万米ドルに成長します。予測期間の成長は、低侵襲手技、医薬イノベーション、遺伝子・エピジェネティック研究、女性ヘルスケアの世界的拡大に起因しています。予測期間における主な動向には、患者中心のケア、精密医療、バーチャルケアと遠隔医療、妊孕性温存などがあります。

卵巣がんの有病率の上昇は、子宮内膜症市場の予想成長の原動力となると思われます。卵巣がんは、卵巣（卵子の生産とホルモン分泌を担う重要な女性の生殖器官）に発生する悪性腫瘍で、子宮内膜症と密接な関係があります。この状態は、特定の卵巣がん亜型、特にエストロゲン濃度の上昇を特徴とする子宮内膜がん亜型および精密細胞がん亜型の開発リスクを高め、卵巣がんリスクを上昇させる。例として、2023年1月の米国がん協会のデータでは、2023年の米国女性の卵巣がんの新規症例は約19,710例と予測されています。さらに、米国を拠点とする非営利団体Ovarian Cancer Research Allianceは、2022年の卵巣がん関連死亡者数を12,810人と報告し、2023年には13,270人に増加すると予測しています。その結果、卵巣がん罹患率の急増が子宮内膜症市場拡大の原動力となっています。

政府助成金の増加は、子宮内膜症市場の成長を促進すると予測されています。政府からの資金援助とは、政府以外の団体に提供される資金援助であり、資金援助の全部または一部は政府団体から提供されます。通常、補助金や契約を通じて提供される政府からの資金援助は、子宮内膜症の研究を促進するのに役立ち、臨床研究を行う個々の研究者や研究機関に利益をもたらします。一例として、米国連邦政府は2022年3月、国立小児保健・人間発達研究所（NICHD）に対して9,200万米ドルの資金拠出を表明しました。国防総省の査読付き医学研究プログラム（PRMRP）は、子宮内膜症研究に3億7,000万米ドルの資金を提供し、実質的な支援を受け続けています。その結果、子宮内膜症市場の成長を促進する上で、政府資金の急増は極めて重要な役割を果たしています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界子宮内膜症PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の子宮内膜症市場：成長率分析
• 世界の子宮内膜症市場の実績：規模と成長, 2019-2024
• 世界の子宮内膜症市場の予測：規模と成長, 2024-2029, 2034F
• 世界子宮内膜症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の子宮内膜症市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腹膜表層病変
• 子宮内膜症
• 深く浸透する子宮内膜症
• その他のタイプ
• 世界の子宮内膜症市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ホルモン療法
• 疼痛管理
• 世界の子宮内膜症市場薬物による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口避妊薬
• プロゲスチン
• 非ステロイド性抗炎症薬（NSAID）
• ゴナドトロピン放出ホルモン（GnRH）類似体
• レボノルゲストレル放出子宮内避妊器具（LNR-IUD）
• その他の薬物
• 世界の子宮内膜症市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門センター
• その他のエンドユーザー
• 世界の子宮内膜症市場、腹膜表在病変のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 子宮内膜症結節
• 腹膜子宮内膜症
• 世界の子宮内膜症市場子宮内膜症のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• チョコレート嚢胞
• 世界の子宮内膜症市場深部浸潤性子宮内膜症の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腸子宮内膜症
• 尿管子宮内膜症
• 膣子宮内膜症
• 世界の子宮内膜症市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腹部子宮内膜症
• 胸部子宮内膜症

第7章 地域別・国別分析

• 世界の子宮内膜症市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の子宮内膜症市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 子宮内膜症市場：競合情勢
• 子宮内膜症市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol-Myers Squibb Company
• GlaxoSmithKline plc
• AstraZeneca plc
• Abbott Laboratories
• Eli Lilly and Company
• Mylan N.V.
• Astellas Pharma Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Limited
• Ipsen Pharma Biotech S.A.S.
• Cadila Pharmaceuticals Ltd.
• Gedeon Richter plc
• Torrent Pharmaceuticals Ltd.
• Neurocrine Biosciences Inc.
• Ferring Pharmaceuticals

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 子宮内膜症市場2029：新たな機会を提供する国
• 子宮内膜症市場2029：新たな機会を提供するセグメント
• 子宮内膜症市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Endometriosis is a chronic medical condition characterized by the growth of tissue similar to the uterine lining (endometrium) outside the uterus. This condition often results in severe pelvic pain and can complicate fertility, significantly impacting an individual's overall well-being and ability to conceive.

Endometriosis presents in various forms, including superficial peritoneal lesions, endometrioma, deeply infiltrating endometriosis, and other less common manifestations. Superficial peritoneal lesions denote a specific type of abnormal tissue growth associated with endometriosis and typically necessitate treatments like hormonal therapy and pain management. Several drugs and therapies are available for managing this condition, including oral contraceptives, progestins, nonsteroidal anti-inflammatory drugs (NSAIDs), GnRH analogs, levonorgestrel-releasing intrauterine devices (LNR-IUDs), among others. These treatments are administered by different healthcare end-users, such as hospitals, homecare services, specialty centers, and others.

The endometriosis market research report is one of a series of new reports from The Business Research Company that provides endometriosis market statistics, including endometriosis industry global market size, regional shares, competitors with an endometriosis market share, detailed endometriosis market segments, market trends and opportunities and any further data you may need to thrive in the endometriosis industry. This endometriosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The endometriosis market size has grown rapidly in recent years. It will grow from $1.4 billion in 2024 to $1.55 billion in 2025 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to delayed diagnosis and increased awareness, advances in laparoscopic surgery, hormonal therapies, patient advocacy and support groups.

The endometriosis market size is expected to see strong growth in the next few years. It will grow to $2.21 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to minimally invasive procedures, pharmaceutical innovations, genetic and epigenetic research, global expansion of women's healthcare. Major trends in the forecast period include patient-centered care, precision medicine, virtual care and telemedicine, fertility preservation.

The escalating prevalence of ovarian cancer is poised to be a driving force behind the anticipated growth of the endometriosis market. Ovarian cancer, a malignancy originating in the ovaries - vital female reproductive organs responsible for egg production and hormone secretion - is intrinsically linked to endometriosis. This condition heightens the risk of developing certain ovarian cancer subtypes, notably the endometrioid and precise cell cancer subtypes characterized by elevated estrogen concentrations, which can elevate ovarian cancer risk. As an illustration, data from the American Cancer Society in January 2023 projects around 19,710 new cases of ovarian cancer among women in the United States for 2023. Additionally, the Ovarian Cancer Research Alliance, a U.S.-based not-for-profit organization, reported 12,810 ovarian cancer-related fatalities in 2022, with a rise to 13,270 expected in 2023. Consequently, the surge in ovarian cancer incidence is a driving factor behind the expansion of the endometriosis market.

The upswing in government funding is anticipated to propel the growth of the endometriosis market. Government funding encompasses financial support provided to non-government entities, wherein all or a portion of the financial backing is supplied by government entities. Typically channeled through grants and contracts, government funding is instrumental in advancing endometriosis research, benefitting individual researchers and research institutions conducting clinical studies. As an example, in March 2022, the U.S. federal government unveiled a commitment of $92 million in funding for the National Institute of Child Health and Human Development (NICHD). The Department of Defense's Peer-Reviewed Medical Research Programme (PRMRP) continues to receive substantial support with $370 million in funding for endometriosis research. Consequently, the upsurge in government funding plays a pivotal role in propelling the growth of the endometriosis market.

Prominent companies engaged in the endometriosis market are placing their focus on the development of innovative medications, including Myfembree, and securing approvals to introduce fresh treatment options for patients. The advent of novel medications for endometriosis addresses a previously unmet need for effective treatments. For instance, in August 2022, Myovant Sciences GmbH, a Switzerland-based biopharmaceutical company, in collaboration with Pfizer Inc., a U.S.-based pharmaceutical industry company, secured approval from the U.S. Food and Drug Administration (FDA) for Myfembree. This medication is designed for the management of moderate to severe pain associated with endometriosis in premenopausal women. Myfembree is a once-daily pill that combines three vital components such as relugolix, estradiol, and norethindrone acetate, offering proven relief to premenopausal women with two indications in a single pill. This presents an alternative treatment choice for women who cannot or prefer not to use hormone therapy.

In February 2022, Theramex, a U.K.-based pharmaceutical company specializing in women's health, particularly in contraception, fertility, menopause, and osteoporosis, entered a partnership with ObsEva SA. The collaboration aims to commercialize Linzagolix, an oral GnRH antagonist, for women experiencing uterine fibroids and endometriosis-related pain, with potential royalties reaching up to USD 80.03 million (EUR 72.75 million). ObsEva SA, a Switzerland-based biopharmaceutical company, focuses on developing and commercializing innovative therapies for women's reproductive health and pregnancy.

Major companies operating in the endometriosis market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck And Co. Inc., Abbvie Inc., Bayer AG, Bristol-Myers Squibb Company, GlaxoSmithKline PLC, AstraZeneca PLC, Abbott Laboratories, Eli Lilly and Company, Mylan N.V., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, Ipsen Pharma Biotech S.A.S., Cadila Pharmaceuticals Ltd., Gedeon Richter PLC, Torrent Pharmaceuticals Ltd., Neurocrine Biosciences Inc., Ferring Pharmaceuticals, Prestige Consumer Healthcare Inc., Almirall S.A, Evotec BioSystems GmbH, Serum Institute of India Pvt. Ltd., Kissei Pharmaceutical Co. Ltd., Sanofi India Ltd., DebioPharm Group, Repros Therapeutics Inc., Meditrina Pharmaceuticals Private Limited, Zenomed Healthcare Private Limited.

North America was the largest region in the endometriosis market in 2024. The regions covered in endometriosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the endometriosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The endometriosis market consists of revenues earned by entities by providing services such as laparoscopy, nutritional counseling, physical therapy, diagnostic laparoscopy, fertility treatment, surgical interventions and complementary therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The endometriosis market also includes sales of birth control pills, patches and vaginal rings. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Endometriosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on endometriosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for endometriosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The endometriosis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Superficial Peritoneal Lesion; Endometrioma; Deeply Infiltrating Endometriosis; Other Types
• 2) By Treatment Type: Hormonal Therapy; Pain Management
• 3) By Drug: Oral Contraceptives; Progestins; Nonsteroidal Anti-Inflammatory Drugs (NSAIDs); Gonadotropin Releasing Hormone (GnRH) Analogues; Levonorgestrel-Releasing Intrauterine Devices (LNR-IUDs); Other Drugs
• 4) By End-User: Hospitals; Homecare; Specialty Centers; Other End-Users
• Subsegments:
• 1) By Superficial Peritoneal Lesion: Endometriotic Nodules; Peritoneal Endometriosis
• 2) By Endometrioma: Chocolate Cysts
• 3) By Deeply Infiltrating Endometriosis: Bowel Endometriosis; Ureteral Endometriosis; Vaginal Endometriosis
• 4) By Other Types: Abdominal Endometriosis; Thoracic Endometriosis
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck And Co. Inc.; Abbvie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Endometriosis Market Characteristics

3. Endometriosis Market Trends And Strategies

4. Endometriosis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Endometriosis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Endometriosis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Endometriosis Market Growth Rate Analysis
• 5.4. Global Endometriosis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Endometriosis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Endometriosis Total Addressable Market (TAM)

6. Endometriosis Market Segmentation

• 6.1. Global Endometriosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Superficial Peritoneal Lesion
• Endometrioma
• Deeply Infiltrating Endometriosis
• Other Types
• 6.2. Global Endometriosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hormonal Therapy
• Pain Management
• 6.3. Global Endometriosis Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Contraceptives
• Progestins
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• Gonadotropin Releasing Hormone (GnRH) Analogues
• Levonorgestrel-Releasing Intrauterine Devices (LNR-IUDs)
• Other Drugs
• 6.4. Global Endometriosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Centers
• Other End-Users
• 6.5. Global Endometriosis Market, Sub-Segmentation Of Superficial Peritoneal Lesion, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Endometriotic Nodules
• Peritoneal Endometriosis
• 6.6. Global Endometriosis Market, Sub-Segmentation Of Endometrioma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chocolate Cysts
• 6.7. Global Endometriosis Market, Sub-Segmentation Of Deeply Infiltrating Endometriosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bowel Endometriosis
• Ureteral Endometriosis
• Vaginal Endometriosis
• 6.8. Global Endometriosis Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Abdominal Endometriosis
• Thoracic Endometriosis

7. Endometriosis Market Regional And Country Analysis

• 7.1. Global Endometriosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Endometriosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Endometriosis Market

• 8.1. Asia-Pacific Endometriosis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Endometriosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Endometriosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Endometriosis Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Endometriosis Market

• 9.1. China Endometriosis Market Overview
• 9.2. China Endometriosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Endometriosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Endometriosis Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Endometriosis Market

• 10.1. India Endometriosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Endometriosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Endometriosis Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Endometriosis Market

• 11.1. Japan Endometriosis Market Overview
• 11.2. Japan Endometriosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Endometriosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Endometriosis Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Endometriosis Market

• 12.1. Australia Endometriosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Endometriosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Endometriosis Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Endometriosis Market

• 13.1. Indonesia Endometriosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Endometriosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Endometriosis Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Endometriosis Market

• 14.1. South Korea Endometriosis Market Overview
• 14.2. South Korea Endometriosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Endometriosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Endometriosis Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Endometriosis Market

• 15.1. Western Europe Endometriosis Market Overview
• 15.2. Western Europe Endometriosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Endometriosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Endometriosis Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Endometriosis Market

• 16.1. UK Endometriosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Endometriosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Endometriosis Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Endometriosis Market

• 17.1. Germany Endometriosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Endometriosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Endometriosis Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Endometriosis Market

• 18.1. France Endometriosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Endometriosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Endometriosis Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Endometriosis Market

• 19.1. Italy Endometriosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Endometriosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Endometriosis Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Endometriosis Market

• 20.1. Spain Endometriosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Endometriosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Endometriosis Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Endometriosis Market

• 21.1. Eastern Europe Endometriosis Market Overview
• 21.2. Eastern Europe Endometriosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Endometriosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Endometriosis Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Endometriosis Market

• 22.1. Russia Endometriosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Endometriosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Endometriosis Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Endometriosis Market

• 23.1. North America Endometriosis Market Overview
• 23.2. North America Endometriosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Endometriosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Endometriosis Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Endometriosis Market

• 24.1. USA Endometriosis Market Overview
• 24.2. USA Endometriosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Endometriosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Endometriosis Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Endometriosis Market

• 25.1. Canada Endometriosis Market Overview
• 25.2. Canada Endometriosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Endometriosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Endometriosis Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Endometriosis Market

• 26.1. South America Endometriosis Market Overview
• 26.2. South America Endometriosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Endometriosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Endometriosis Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Endometriosis Market

• 27.1. Brazil Endometriosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Endometriosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Endometriosis Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Endometriosis Market

• 28.1. Middle East Endometriosis Market Overview
• 28.2. Middle East Endometriosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Endometriosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Endometriosis Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Endometriosis Market

• 29.1. Africa Endometriosis Market Overview
• 29.2. Africa Endometriosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Endometriosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Endometriosis Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Endometriosis Market Competitive Landscape And Company Profiles

• 30.1. Endometriosis Market Competitive Landscape
• 30.2. Endometriosis Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Endometriosis Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. GlaxoSmithKline plc
• 31.3. AstraZeneca plc
• 31.4. Abbott Laboratories
• 31.5. Eli Lilly and Company
• 31.6. Mylan N.V.
• 31.7. Astellas Pharma Inc.
• 31.8. Sun Pharmaceutical Industries Ltd.
• 31.9. Teva Pharmaceutical Industries Limited
• 31.10. Ipsen Pharma Biotech S.A.S.
• 31.11. Cadila Pharmaceuticals Ltd.
• 31.12. Gedeon Richter plc
• 31.13. Torrent Pharmaceuticals Ltd.
• 31.14. Neurocrine Biosciences Inc.
• 31.15. Ferring Pharmaceuticals

32. Global Endometriosis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Endometriosis Market

34. Recent Developments In The Endometriosis Market

35. Endometriosis Market High Potential Countries, Segments and Strategies

• 35.1 Endometriosis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Endometriosis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Endometriosis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer